BIO — BIO-RAD LABORATORIES, INC.

—
NYSE · Unknown · Unknown · CIK 12208 ·
Last close
$358.19
Market Cap
$7.82B
52W High
$396.23
52W Low
$236.73
ADV30
242,284
Next earnings
2026-11-04

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 656,400,000 328,600,000 100,000 458,600,000 10,783,100,000 465,300,000 3,180,100,000
Jun 2026 651,000,000 345,800,000 72,600,000 371,400,000 10,252,000,000 517,000,000 3,078,100,000
Mar 2026 592,100,000 309,400,000 34,100,000 -527,100,000 9,790,000,000 507,200,000 2,938,700,000
Dec 2025 693,200,000 345,200,000 53,900,000 720,000,000 10,576,500,000 529,800,000 3,122,900,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$468,100,000
Investing CF
$-340,000,000
Financing CF
$-69,900,000
CapEx
$-139,000,000
Dividends Paid
—
Buybacks
$-79,300,000
EPS Diluted TTM
$37.97
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$8,479,200,000
Inventory
$783,900,000
Receivables
$422,600,000
ST Investments
$1,199,000,000
EBIT TTM
$1,369,000,000
Pretax Income TTM
$1,320,200,000
Interest Exp TTM
$48,800,000
Analysts
3

Yahoo Snapshot (yfinance, live)

Total Revenue
$2,592,699,904
EBITDA
$410,900,000
Free Cash Flow
$271,649,984
Enterprise Value
$9,960,640,512
Total Cash
$1,664,300,032
Total Debt
$1,363,399,936
Shares Out
21,832,130
Trailing EPS
$37.64
Book Value
$282.74
ROE
14.3%
ROA
1.5%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 2,583,200,000 218,600,000 759,900,000 10,576,500,000 3,122,900,000 7,453,600,000 532,200,000
Dec 2024 2,566,500,000 269,000,000 -1,844,200,000 9,364,100,000 2,794,800,000 6,569,300,000 455,200,000
Dec 2023 2,671,200,000 337,800,000 -637,300,000 12,299,100,000 3,557,900,000 8,741,200,000 374,900,000
Dec 2022 2,802,200,000 475,100,000 -3,627,500,000 13,501,666,000 3,886,414,000 9,615,252,000 194,400,000

TTM Snapshot

Revenues TTM
$2,589,300,000
NetIncome TTM
$222,400,000
OpCashFlow TTM
—
Assets (Latest)
$10,252,000,000
Forward EPS
$9.65

Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)

max pain strike: $290.00 · spot: $370.17 · call volume: 79 · put volume: 8
Expected Move to 2026-12-18: ±$49.85 (13.47%) — implied range $320.32 – $420.02 · ATM straddle on $370.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
WEIGF Weir Group PLC/ADR $7.81B $30.09 —
WEGRY Weir Group PLC/ADR $7.79B $15.01 —
JCYGY Jardine Matheson Southeast Asia Limited/ADR $8.00B $40.46 —
TME Tencent Music Entertainment Group $7.55B $9.47 —
FCFS FirstCash Holdings, Inc. $7.53B $175.62 —

News headlines (Yahoo Finance, 1h cache)

2026 Global Screener Proficiency Testing Platform Market: $2.01 Billion Forecast for 2030 | Capitalize on AI and Cloud Demand with Thermo Fisher, Merck, Bio-Rad, and Randox
2026-11-13 14:33 · Yahoo
Cell Lysis / Cell Fractionation - Global Strategic Business Report 2026: Capture the $4.5 Billion Market by 2032 | Features Competitive Intelligence on Thermo Fisher, Beckman Coulter, Bio-Rad, Qiagen
2026-11-12 15:00 · Yahoo
Microfluidic Device Systems - Global Strategic Business Report 2026: Capitalize on 8.7% CAGR to $11.1 Billion by 2032 | Abbott, Danaher, Bio-Rad, and Siemens Healthineers Shape the Competition
2026-11-12 14:57 · Yahoo
Transfection Technologies - Global Strategic Business Report 2026: Capitalize on a $2.5 Billion Market by 2032 as Thermo Fisher, Lonza, Bio-Rad, Qiagen and MilliporeSigma Accelerate
2026-11-11 14:21 · Yahoo
Single-Cell Analysis - Global Strategic Business Report 2026: Capitalize on 20.4% CAGR as Illumina, Thermo Fisher Scientific, Bio-Rad and Agilent Battle for Shares in the $26.1 Billion Market by 2032
2026-11-11 14:18 · Yahoo
Molecular Cytogenetics - Global Strategic Business Report: Capitalize on 8.8% CAGR to US$3.5 Billion by 2030; Outmaneuver Abbott, Agilent, Bio-Rad, Illumina and Roche Amid Tariff Shifts
2026-11-11 14:13 · Yahoo
Capillary Electrophoresis - Global Strategic Business Report: Secure Share of the $1.1 Billion Market by 2032 as Agilent, Bio-Rad, Danaher and Thermo Fisher Accelerate CE-MS Innovation
2026-11-10 15:11 · Yahoo
Nucleic Acid Isolation and Purification - Global Strategic Business Report: Capture the $3.9 Billion Revenue Surge by 2030 as Thermo Fisher, Qiagen, Danaher, Illumina, and Bio-Rad Battle for Share
2026-11-10 15:02 · Yahoo
Gene Amplification Technologies - Global Strategic Business Report: Capture $4.4B in New Revenue by 2030 as Abbott, Bio-Rad, bioMerieux, Cepheid and Becton Dickinson Battle for Share
2026-11-10 14:20 · Yahoo
How Investors Are Reacting To Bio Rad (BIO) International Revenue Surprise
2026-11-10 11:08 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.